Normal T cell subsets and lymphocyte activity in multiple sclerosis. (2024)

PMCID: PMC1577277

M M Albala, D Davignon, L D Fast, and D D Clark

Copyright and License information PMC Disclaimer

Abstract

Nine patients with either chronic progressive or relapsing/remitting multiple sclerosis were treated with several courses of lymphopheresis. The lymphocytes obtained by this procedure showed a significantly lower percentage of OKT3+ cells than normal controls at the beginning of therapy. This percentage increased to normal levels after five lymphopheresis treatments and then decreased during the last stages of treatment. Patients had normal levels of OKT4+ and OKT8+ cells compared to controls and these percentages showed no statistically significant changes during the course of treatment. The proliferative response of patient's lymphocytes after stimulation with concanavalin A, PHA and alloantigen was not significantly different from normal controls and these responses were unchanged during the lymphopheresis treatment. Natural killer cell activity was also normal in our patients. The results reported in this study do not suggest a basic T cell abnormality in our patients with multiple sclerosis. Furthermore, the lymphopheresis treatments did not induce any significant change in T cell numbers or functional activity in vitro.

• Abramsky O, Lisak RP, Silberberg DH, Pleasure DE. Antibodies to oligodendroglia in patients with multiple sclerosis. N Engl J Med. 1977 Dec 1;297(22):1207–1211. [PubMed] [Google Scholar]
• Antel JP, Arnason BG, Medof ME. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol. 1979 Apr;5(4):338–342. [PubMed] [Google Scholar]
• Antel J, Oger JJ, Jackevicius S, Kuo HH, Arnason BG. Modulation of T-lymphocyte differentiation antigens: potential relevance for multiple sclerosis. Proc Natl Acad Sci U S A. 1982 May;79(10):3330–3334. [PMC free article] [PubMed] [Google Scholar]
• Bach MA, Phan-Dinh-Tuy F, Tournier E, Chatenoud L, Bach JF, Martin C, Degos JD. Deficit of suppressor T cells in active multiple sclerosis. Lancet. 1980 Dec 6;2(8206):1221–1223. [PubMed] [Google Scholar]
• Benczur M, Petrányl GG, Pálffy G, Varga M, Tálas M, Kotsy B, Földes I, Hollán SR. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol. 1980 Mar;39(3):657–662. [PMC free article] [PubMed] [Google Scholar]
• Compston A. Lymphocyte subpopulations in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 1983 Feb;46(2):105–114. [PMC free article] [PubMed] [Google Scholar]
• Dropcho EJ, Richman DP, Antel JP, Arnason BG. Defective mitogenic responses in myasthenia gravis and multiple sclerosis. Ann Neurol. 1982 May;11(5):456–462. [PubMed] [Google Scholar]
• Dwyer JM, Wade MJ, Katz AJ. Removal of thymic-derived lymphocytes during pheresis procedures. Vox Sang. 1981 Nov-Dec;41(5-6):287–294. [PubMed] [Google Scholar]
• Hauser SL, Reinherz EL, Hoban CJ, Schlossman SF, Weiner HL. Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period. Ann Neurol. 1983 Apr;13(4):418–425. [PubMed] [Google Scholar]
• Kam-Hansen S, Andersson R, Link H. Cerebrospinal fluid lymphocytes from patients with multiple sclerosis and aseptic meningo-encephalitis respond in mixed lymphocyte culture. J Neuroimmunol. 1983 Aug;5(1):67–81. [PubMed] [Google Scholar]
• Mattson DH, Roos RP, Arnason BG. Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains. Nature. 1980 Sep 25;287(5780):335–337. [PubMed] [Google Scholar]
• Merrill J, Jondal M, Seeley J, Ullberg M, Sidén A. Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity in the disease. Clin Exp Immunol. 1982 Feb;47(2):419–430. [PMC free article] [PubMed] [Google Scholar]
• Paty DW, Kastrukoff L, Morgan N, Hiob L. Suppressor T-lymphocytes in multiple sclerosis: analysis of patients with acute relapsing and chronic progressive disease. Ann Neurol. 1983 Oct;14(4):445–449. [PubMed] [Google Scholar]
• Reinherz EL, Kung PC, Goldstein G, Schlossman SF. Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci U S A. 1979 Aug;76(8):4061–4065. [PMC free article] [PubMed] [Google Scholar]
• Reinherz EL, Kung PC, Goldstein G, Schlossman SF. A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2. J Immunol. 1980 Mar;124(3):1301–1307. [PubMed] [Google Scholar]
• Reinherz EL, Weiner HL, Hauser SL, Cohen JA, Distaso JA, Schlossman SF. Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med. 1980 Jul 17;303(3):125–129. [PubMed] [Google Scholar]
• Rice GP, Casali P, Merigan TC, Oldstone MB. Natural killer cell activity in patients with multiple sclerosis given alpha interferon. Ann Neurol. 1983 Sep;14(3):333–338. [PubMed] [Google Scholar]
• Rose J, Klein H, Greenstein J, McFarlin D, Gerber L, McFarland H. Lymphocytapheresis in chronic progressive multiple sclerosis: results of a preliminary trial. Ann Neurol. 1983 Nov;14(5):593–594. [PubMed] [Google Scholar]
• Santoli D, Hall W, Kastrukoff L, Lisak RP, Perussia B, Trinchieri G, Koprowski H. Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis. J Immunol. 1981 Apr;126(4):1274–1278. [PubMed] [Google Scholar]
• Schocket AL, Weiner HL, Walker J, McIntosh K, Kohler PF. Lymphocytotoxic antibodies in multiple sclerosis. Clin Immunol Immunopathol. 1977 Jan;7(1):15–23. [PubMed] [Google Scholar]
• Scott CF, Spitler LE. Lymphocytotoxic antibody in multiple sclerosis: activity against T cell subsets and correlation with disease activity. Clin Exp Immunol. 1983 Jul;53(1):133–139. [PMC free article] [PubMed] [Google Scholar]
• Uchida A, Maida EM, Lenzhofer R, Micksche M. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis. Immunobiology. 1982 Feb;160(5):392–402. [PubMed] [Google Scholar]
• Vervliet G, Claeys H, Van Haver H, Carton H, Vermylen C, Meulepas E, Billiau A. Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients. J Neurol Sci. 1983 Jul;60(1):137–150. [PubMed] [Google Scholar]
• Wright DG, Karsh J, Fauci AS, Klippel JH, Decker JL, O'Donnell JF, Deisseroth AB. Lymphocyte depletion and immunosuppression with repeated leukapheresis by continuous flow centrifugation. Blood. 1981 Sep;58(3):451–458. [PubMed] [Google Scholar]
• Ziegler JB, Hansen PJ, Davies WA, Penny R. The PHA dose-response curve: validation of the use of logarithmic graph paper by computer analysis results. J Immunol. 1974 Dec;113(6):2035–2039. [PubMed] [Google Scholar]